I think it depends how big you think the drug can be. Certainly a case can be made that there is still room to grow if you believe the $9B estimate by the DB analyst. And there is also likely more upside once this company starts being valued on EPS. With its growth rate pcyc likely will command a premium P/E. I think we are only in the 3rd inning here long term. Think REGN. Only better.